Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Say goodbye to daily insulin shots. The FDA has approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. Backed by a late-stage trial of over 3,400 patients, Onswik demonstrated blood sugar reductions non-inferior to daily insulin glargine — potentially cutting injections by more than 300 per year.
Once a week is the new once a day — at least for insulin. The FDA has approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes, marking a meaningful shift in how the condition can be managed. Designed to be used alongside diet and exercise, Onswik will be available as a pre-filled KwikPen in two concentrations (500 and 1,000 units/mL) in the coming months.
The approval was based on four late-stage studies enrolling more than 3,400 adults with type 2 diabetes. Onswik met its primary endpoint in each study, demonstrating A1C reductions non-inferior to daily insulin glargine (e.g., Lantus, Basaglar). Notably, Onswik is not indicated for type 1 diabetes due to an elevated risk of severe hypoglycemia.
Key Takeaways:
Why it matters: For the millions of Americans managing type 2 diabetes, a once-weekly insulin option could meaningfully improve adherence and quality of life — reducing injection burden and simplifying daily routines.
